Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 3

ACURA PHARMACEUTICALS, INC

Form 3

October 25, 2007

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

Common Stock (1) (2)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement ACURA PHARMACEUTICALS, INC [ACUR.OB] Seiser Robert A (Month/Day/Year) 10/25/2007 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O ACURA (Check all applicable) PHARMACEUTICALS, INC.. 616 N. NORTH COURT 10% Owner Director **SUITE 120** _X__ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group VP, Controller & Treasurer Filing(Check Applicable Line) _X_ Form filed by One Reporting Person PALATINE, ILÂ 60067 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)

2. Amount of Securities 3.
Beneficially Owned Owner
(Instr. 4) Form:
Direct

1,650,000

3. 4. Nature of Indirect Beneficial Ownership Ownership Form: (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and Expiration Date
(Month/Day/Year)

2. Date Exercisable and Securities Underlying
Derivative Security

3. Title and Amount of Securities Underlying
Conversion
Ownership
Or Exercise
Form of (Instr. 5)

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 3

		Expiration Date	(Instr. 4)		Price of	Derivative	
Date Exercisabl	Date Exercisable		Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Options	(3)	03/08/2009	Common Stock	16,000	\$ 1.125	D	Â
Employee Stock Options	(3)	11/15/2011	Common Stock	25,000	\$ 2.46	D	Â
Employee Stock Options	(3)	02/17/2010	Common Stock	30,000	\$ 1.875	D	Â
Employee Stock Options	(3)	05/29/2008	Common Stock	40,000	\$ 2.5	D	Â
Employee Stock Options	(3)	06/29/2010	Common Stock	40,000	\$ 1.1125	D	Â
Employee Stock Options	(4)	03/09/2014	Common Stock	249,000	\$ 0.13	D	Â

Reporting Owners

Reporting Owner Name / Address		Relationships					
. 9	Director	10% Owner	Officer	Other			
Seiser Robert A							
C/O ACURA PHARMACEUTICALS, INC.	Â	Â	VP, Controller & Treasurer	Â			
616 N. NORTH COURT SUITE 120			11 (1, 00111101101 00 1101101101				
PALATINE, IL 60067							

Signatures

/s/ Robert Seiser 10/25/2007

**Signature of Pate Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Holdings listed are Restricted Stock Units. Restricted Stock Units represent rights to an equivalent number of shares of common stock of (1) the Issuer. Upon receipt of Common Stock under the Restricted Stock Units, holders of Restricted Stock Units must pay par value (\$.01) for each share acquired.
 - Restricted Stock Units vest as follows: 550,000 of such units vested upon issuance on 12/22/2005 (the grant date) and 15,277.9 (2.7778%) of such units vest on each of the first 24 monthly anniversaries of the grant date. Absent a change of control, 412,500 shares of common stock will be distributed under the Restricted Stock Units (after payment of \$.01 par value per share par value) on January 1st of
- (2) each of 2011, 2012, 2013 and 2014. If a change of control occurs (whether prior to or after 2011), one share common stock will be distributed for each outstanding Restricted Stock Unit (after payment of \$0.01 per share par value) at or about the time of the change of control.

(3) Options are currently exercisable

(4)

Reporting Owners 2

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 3

Options vest with respect to 25% of the underlying shares on March 9th of each of 2005, 2006, 2007 and 2008, and upon the occurrence of certain events. Vested options are exercisable on the earliest of termination of employment, January 1, 2011 and a change of control.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.